Abstract:Background Genome wide genetic/epigenetic studies are revealing more risk loci associated with the Alzheimer’s disease (AD). One recent analysis of human epigenome‐wide association studies (EWAS) reports an association between variations in the gene PM20D1 and AD, showing hypermethylation in the brain tissues in patients with advanced‐stage AD. Methods We used whole genome DNA methylation data collected from peripheral blood mononuclear cells (PBMCs) in a cohort (n = 649) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and compared the DNA methylation level at baseline among different diagnosis groups. We also leveraged the longitudinal data up to 4 years, sampled at approximately 1 year intervals to model the alterations in the methylation levels detected at the differentially methylated regions (DMRs) to delineate the methylation change course over aging and disease progression. The dynamic pattern of DNA methylation level with disease progression at the PM20D1 locus in brain tissues were also modeled from the data in The Religious Orders Study and Memory and Aging Project (ROSMAP) Study cohort (n = 740). Results When compared with controls, patients with mild cognitive impairment (MCI) consistently displayed promoter hypomethylation at reported methylation QTL gene locus PM20D1. This promoter hypomethylation was even more prominent in patients with mild to moderate AD. This is in stark contrast with previously reported hypermethylation in brain tissues in patients with advanced‐stage AD. By leveraging longitudinal DNA methylation data, linear mixed‐effects (LME) modeling for the unchanged diagnosis groups and U‐shape testing for those with changed diagnosis (converters) indicate that, we observe initial promoter hypomethylation of PM20D1 during MCI and early stage AD, which reverses to eventual promoter hypermethylation in the transition to late stage AD. We also confirm this observation in ROSMAP cohort as neuropathology deteriorates. Correlation of DNA methylation between blood and brain tissues at PM20D1 promoter region also demonstrates the pattern is consistent across tissues. Conclusions Our results confirm that PM20D1 is an mQTL for AD and demonstrate that it plays a dynamic role at different stages of the disease. Further in‐depth study is thus warranted to fully decipher its role in the evolution of AD, and potentially explore its utility as a blood‐based biomarker for AD.

Genome-wide Analysis of DNA Methylation Profiles in a Senescence-Accelerated Mouse Prone 8 Brain Using Whole-Genome Bisulfite Sequencing.

Genome-wide Methylomic Regulation of Multiscale Gene Networks in Alzheimer's Disease

Erratum To: Genome-wide Analysis of DNA Methylation in an APP/PS1 Mouse Model of Alzheimer’s Disease

Epigenome-wide DNA methylation analysis of late-stage mild cognitive impairment

Changes in methylation patterns of multiple genes from peripheral blood leucocytes of Alzheimer's disease patients.

Longitudinal data in peripheral blood confirm that PM20D1 is a quantitative trait locus (QTL) for Alzheimer’s disease and implicate its dynamic role in disease progression

Genome-wide Survey Reveals Dynamic Widespread Tissue-Specific Changes in DNA Methylation During Development

Longitudinal data in peripheral blood confirms PM20D1 is a quantitative trait locus (QTL) for Alzheimer’s disease and implicates its dynamic role in disease progression

Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects

DNA methylation in Alzheimer’s disease: In brain and peripheral blood

Rescue of Early bace-1 and Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves Cognition in an Alzheimer’s Model

Characterization of Circrna-Associated-cerna Networks in a Senescence-Accelerated Mouse Prone 8 Brain.

APOE Genotype-specific Methylation Patterns are Linked to Alzheimer Disease Pathology and Estrogen Response

Integrated Genome-Wide Analysis of DNA Methylation and Gene Expression in the Hippocampi of 5xFAD Alzheimer's Disease Mouse Model

Integrated Analyses of 5mc, 5hmc Methylation and Gene Expression Reveal Pathology-Associated AKT3 Gene and Potential Biomarkers for Alzheimer’s Disease

Epigenetic Signatures of Methylated DNA Cytosine in Alzheimer’s Disease

Mechanisms underlying LncRNA SNHG1 regulation of Alzheimer's disease involve DNA methylation

Blood DNA Methylation Signature for Incident Dementia: Evidence from Longitudinal Cohorts

Analyses of Mrna Profiling Through RNA Sequencing on a SAMP8 Mouse Model in Response to Ginsenoside Rg1 and Rb1 Treatment

A Bioinformatics-Based Study on Methylation Alterations of the FBLN1 Gene in Hippocampal Tissue of Alzheimer's Disease Model DKO and DTG Mice

DNA methylation: The epigenetic mechanism of Alzheimer's disease